First Time Loading...

Lyra Therapeutics Inc
NASDAQ:LYRA

Watchlist Manager
Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc
NASDAQ:LYRA
Watchlist
Price: 4.85 USD 2.75%
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

LYRA Price Targets Summary
Lyra Therapeutics Inc

Wall Street analysts forecast LYRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYRA is 12.24 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.

LYRA Lowest Forecast
Wall Street Target
10.1 USD
108% Upside
LYRA Average Forecast
Wall Street Target
12.24 USD
152% Upside
LYRA Highest Forecast
Wall Street Target
15.75 USD
225% Upside
Lowest
Price Target
10.1 USD
108% Upside
Average
Price Target
12.24 USD
152% Upside
Highest
Price Target
15.75 USD
225% Upside
Lyra Therapeutics Inc Competitors:
Price Targets
S
4565
Sosei Group Corp
57% Upside
NGM
NGM Biopharmaceuticals Inc
10% Upside
600521
Zhejiang Huahai Pharmaceutical Co Ltd
6% Upside
1760
Panion & BF Biotech Inc
13% Upside
S
4565
Sosei Group Corp
57% Upside
NGM
NGM Biopharmaceuticals Inc
10% Upside
600521
Zhejiang Huahai Pharmaceutical Co Ltd
6% Upside
1760
Panion & BF Biotech Inc
13% Upside
VENUSREM
Venus Remedies Ltd
21% Upside
VETO
Vetoquinol SA
10% Upside
T
TRUL
Trulieve Cannabis Corp
51% Upside

Revenue
Forecast

Revenue Estimate
Lyra Therapeutics Inc

The compound annual growth rate of Lyra Therapeutics Inc's revenue for the next 3 years is 171%.

N/A
Past Growth
171%
Estimated Growth
Estimates Accuracy
-72%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Lyra Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Lyra Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-63%
Average Miss
What are analyst estimates?

See Also

Summary
LYRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
LYRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LYRA stock valuation using valuation multiples.
Wall Street Estimates
LYRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LYRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYRA's stock price target?
Price Target
12.24 USD

According to Wall Street analysts, the average 1-year price target for LYRA is 12.24 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.

What is Lyra Therapeutics Inc's Revenue forecast?
Projected CAGR
171%

The compound annual growth rate of Lyra Therapeutics Inc's revenue for the next 3 years is 171%.

ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.